Clinical Trials
11 trialsNCT03962543 2026-05-06
ReNeu
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2 Active not recruiting
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT02101736 2023-05-24
NF105-CABO
University of Alabama at Birmingham
Phase 2 Completed
NCT01682811 2021-06-18
Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Medical College of Wisconsin
Phase 1 Completed
NCT03513757 2020-02-21
Dexmedetomidine and Propofol for Pediatric MRI Sedation
Medical College of Wisconsin
Phase 4 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01402817 2018-03-14
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Indiana University
Phase 2 Terminated
NCT01140360 2017-07-02
0908-09
Indiana University
Phase 1/2 Completed
NCT01275586 2017-04-12
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Indiana University
Phase EARLY_PHASE1 Completed
NCT01673009 2016-04-06
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Indiana University
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed